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Mononuclear phagocytes represent a key element for the orchestration of the innate and adaptive immune responses, playing a central role in host defence and inflammation (1, 2). In particular, cells of the monocyte/macrophage lineage are essential for the maintenance of tissue homeostasis in healthy conditions as well as for the resistance against pathogens and restoration and repair of tissue integrity after damage (3, 4). 
During ontogenesis, macrophages participate to tissue remodelling in different organs such as bones, mammary glands, pancreas and nervous systems, where they contribute to the organization of the extracellular matrix (ECM), cell proliferation and angiogenesis (5). Moreover, during pregnancy, macrophages localize at the interface between fetus and mother in decidua and placenta, where they exert immunosuppressive actions (6, 7). 
Upon injury, macrophages accumulate in the damaged tissues, initially contributing to the establishment of an inflammatory response (through the production of TNF, IL-1 and nitric oxide) and subsequently orchestrating the resolution of inflammation and the reparative processes (3, 8–10). This dual function perfectly reflects the heterogeneity and plasticity of the monocyte/macrophage lineage: signals derived from the different microenvironment trigger distinct genetic programmes in differentiating macrophages, resulting in the induction of different polarization states. Over-simplifying the complexity of a broad spectrum of differentiating states, macrophages can orient to an M1 (or classically activated) state and M2 (or alternatively activated) state (11). Microbial stimuli (such as LPS) and pro-inflammatory cytokines (e.g. IFN or TNF) induce M1 macrophage polarization: they sustain the host response against bacterial infection and produce immunostimulatory cytokines (such as IL-12, IL-6, IL-1, IL-23 and TNF) and effector mediators of the immune response (such as reactive oxygen species, ROS) (12, 13). In addition, M1 macrophages display cytotoxic activities toward cancer cells and promote tumor resistance (14). In contrast, IL-4 and IL-13 induce alternatively activated M2 macrophage, which are able to suppress Th1 T-cell response and are poor antigen-presenting cells. While the activation of M1 macrophages and their products result in or amplify ongoing tissue damage, M2 macrophages contribute to the dampening of inflammation, angiogenesis, scavenging of debris and tissue remodelling and repair (15). 
	Mirroring the differences in their functions, M1 and M2 macrophages display distinct chemokine profiles, orchestrating the recruitment of different leukocyte populations: M1-polarized macrophages are generally associated with the expression of Th1 cell-attracting chemokines, such as CXCL9 and CXCL10, while M2-polarized macrophages are responsible for the recruitment of Th2 lymphocytes, regulatory T cells (Treg), eosinophils and basophils, through the secretion of chemokines including CCL17, CCL22 and CCL24 (16, 17). 
During the phases of tissue repair, macrophages undergo dynamic changes. Initially M1-polarized macrophages are responsible for the triggering of the inflammatory response, while the switching to an M2 phenotype is crucial for the resolution of inflammation (3, 18). In particular, when a large number of apoptotic cells are generated during tissue injury and inflammation, macrophages accumulate and rapidly exert their clearing activity (19). It has been demonstrated that defects in the clearance of apoptotic cells occur in patients with systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) (20, 21). Conversely mice deficient in molecules involved in the apoptotic cell recognition and clearance develop systemic autoimmunity (22–24).  The delay in the elimination of apoptotic cells favours post-apoptotic necrosis and the release of intracellular autoantigens and adjuvants, in turn favouring autoimmune responses. 
Changes in the composition of the apoptotic cell membrane facilitate the recognition of dying cells by phagocytes. The most common modification, occurring in the very early phase of apoptotic process, is the loss of membrane phospholipid asymmetry, with the externalization of anionic phospholipids such as phosphatidylserine (PS) (25, 26) associated to dramatic metabolic changes and to the relocalization of intracellular components, (such as the endoplasmic reticulum protein calreticulin CRT and various nuclear antigens) (27–29). On the other hand, phagocytes express an apparently redundant array of receptors for the recognition and engulfment of apoptotic cells, such as the PS receptor T-cell immunoglobulin and mucin-domain-containing molecule (TIM-1 and TIM-4), the CD36/V3 complex, TAM receptor tyrosine kinases such as  MERTK together with their agonists and member of the scavenger receptor family, such as SR-A1, stabilin-2 or the lectin-like oxidized low-density-lipoprotein (ox-LDL) receptor-1 (30–33). PS exposure and its recognition via receptors that share scavenging properties condition macrophages, prompting responses that lead to the resolution of inflammatory responses and the regeneration of injured tissues (33, 34). 
Macrophages do not only dispose of dying cells on their own. They also coordinate non-professional phagocytes - such as epithelial cells - to internalize and to respond to particulate substrates and to extracellular vescicles of various size, eventually quenching tissue inflammation in vivo (35). The recognition of apoptotic cells is critical for the proliferation of macrophages that reside in infected/inflamed organs and for the induction of genes associated to tissue regeneration genes. In contrast, induction of macrophages pattern recognition receptors (PRRs), cell adhesion or chemotaxis genes in response to pleiotropic cytokines, including IL-4/IL-13, appears to be independent of the interaction with apoptotic cells (36).
Changes occurring on the surface of apoptotic cells are detected by proteins that bridge phagocytes and target cells and modulate how the particulate substrates are perceived and recognized by phagocytes. Among these, the molecules milk-fat-globule-EGF-factor 8 (MFG-E8), 2-glycoprotein I (2-GPI), growth arrest-specific 6 (Gas6) and serum protein S bind to PS exposed on the membrane of apoptotic cells (19, 37). In addition, macrophages recognize damaged cells via PRRs located on the cell surface, such as toll-like receptors (TLR), dectins, inflammasomes and nucleic acid sensors (38–40). 
Fluid phase pattern recognition molecules (PRMs) and complement components contribute to the opsonisation of apoptotic cells, facilitating their engulfment by macrophages. In addition to complement components, PRMs include mannose binding lectin (MBL), surfactant proteins, ficolins and pentraxins. Pentraxins are key elements of the humoral arm of the innate immunity (41, 42): they include the classic short pentraxin C reactive protein (CRP), serum amyloid P component (SAP) and the long pentraxin PTX3. CRP, SAP and PTX3 bind to apoptotic cells, assisting their recognition and clearance by phagocytes and contributing to tissue healing (43, 44). Here we will review how pentraxins serve as fluid phase PRRs, that sense cell and tissue damage. In concert with chemokines, they regulate leukocyte recruitment and activation at sites of inflammation and as such play a crucial role in the outcome of the inflammatory response. 

Pentraxins: PTX3. 
The innate immune system is composed by a cellular and a humoral arm. Humoral innate immunity comprises the complement system and soluble PRMs (45). Among PRMs, pentraxins comprise a superfamily of highly conserved molecules having regulatory properties in inflammatory conditions. Prototypes of this family are the short or “classical” pentraxins C-reactive protein (CRP) and serum amyloid P component (SAP), and the more recently identified long pentraxin, PTX3.
Pentraxins are phylogenetically conserved proteins, sharing a ~ 200 amino acid long domain characterized by the presence of the so-called “pentraxin signature” (His-x-Cys-x-Ser/Thr-Trp-x-Ser, where “x” represents any amino acid) (46). The short pentraxins CRP and SAP have a peculiar quaternary structure with five or ten protomer subunits organized in symmetric pentamers (47). The human CRP gene, located on chromosome 1q23.2 locus, comprises two exons, encoding for the leader peptide (amino acids 1-18), the two initial amino acids of the mature protein (amino acids 19-20) and the remaining sequence (amino acids 21-224) (48, 49). Structurally, CRP is composed by five identical non-glycosylated subunits, stabilized by a highly conserved intra-chain disulphide bonds (50). The human SAP gene has been mapped on chromosome 1, sharing with CRP the same exon/intron architecture and coding for 51% identical protein sequence. SAP is a plasma glycoprotein, composed by 5 or 10 subunits, non-covalently associated into pentameric rings. Both CRP and SAP are soluble PRMs, able to recognize pathogen associated molecular patterns (PAMPs) as well as danger associated molecular patterns (DAMPs) (51). They opsonize pathogens and apoptotic cells, favouring their complement-mediated clearance (52).
 CRP represents a prototypic acute phase protein, mainly synthesized in the liver upon IL-1 and IL-6 stimulation. It recognizes microbes and apoptotic cells through the membrane expression of phosphocoline (PC) moieties in a calcium-dependent manner. CRP binding to PC-expressing cells leads to the activation of the classical pathway of the complement, with the subsequent opsonisation and phagocytosis (53). Recently, SAP has been demonstrated to contribute to the maintenance of the plasmatic levels of coagulation factor X (FX), mediating its uptake and internalization by scavenging macrophages (54). 
PTX3 is the first long pentraxin to be identified (46). Human PTX3 gene is located on chromosome 3q25 locus and it is composed by 3 exons, encoding for the leader peptide, the long N-terminal domain (amino acids 18-178) and the C-terminal pentraxin-like domain (amino acids 179-381). While the C-terminal domain is homologue to the short pentraxin CRP and SAP, the long N-terminal domain has no sequence similarity to other known proteins. Moreover, PTX3 primary sequence is highly conserved among animal species (human and murine proteins share 92% of conserved amino acids), suggesting a strong evolutionary pressure to preserve both its structure and function (55, 56). Structurally, PTX3 is a 340 kDa octameric protein, composed by eight identical protomers interacting through both inter- and intra-chain disulphide bonds (57). Proximal promoters of both human and murine PTX3 gene share several regulatory elements, such as Pu1, SP1, NF-B, AP-1 and NF-IL-6. While AP-1 mediated PTX3 basal transcription, NF-B site is required for its transcriptional activation in inflammatory conditions (58–60). 
Despite the relative similarity in their sequence, PTX3, CRP and SAP differ in terms of producing cells and inducing stimuli. While CRP and SAP are mainly produced by liver upon IL-6 induction, PTX3 is secreted by different cell types in response to different stimuli. Toll-like receptor, inflammatory cytokines (such as IL-1 and TNF), microbial moieties (LPS or OmpA) and microorganisms induce the secretion of PTX3 by a variety of cell types, including dendritic cells (DCs), macrophages, fibroblasts, synovial cells, chondrocytes, adipocytes, mesangial cells, granulosa cells and glial cells (46, 61, 62). PTX3 expression is stimulated in endothelial cells and vascular smooth muscle cells (SMCs) in response to modified low density lipoproteins (ox-LDL) and anti-inflammatory high-density lipoproteins stimulation, while it is constitutive in lymphatic endothelial cells (63, 64). Polymorphonuclear cells do not express PTX3 mRNA, but a reservoir of the protein is synthesized during differentiation in the bone marrow, stored in lactoferrin-positive granules and released in response to TLR engagement (65) and in the very early phases of acute myocardial infarction, when circulating neutrophils and platelets undergo a transient burst of activation and reciprocal interaction (66). On the contrary, neither T and B lymphocytes or NK cells express PTX3 mRNA (67).
Based on its quaternary structure, PTX3 interacts with a variety of ligands, exerting various biological activities. The complement component C1q is the first described ligand of PTX3 (68, 69). PTX3 binds C1q in calcium-independent manner. The interaction with surface-bound C1q leads to the activation of the classical complement cascade, with the subsequent deposition of the complement components C3 and C4. In contrast, fluid-phase PTX3-C1q interaction results in the inhibition of the complement activation via competitive blocking of relevant interaction sites (69).  PTX3 also binds to components of the lectin pathway (LCP), such as ficolin-1, ficolin-2 and mannose-binding lectin (MBL), enhancing complement deposition on microbial pathogens (e.g. Aspergillus fumigatus or Candida albicans) (70, 71). Finally, PTX3 interacts with negative regulators of the complement activation, such as Factor H and C4BP. Binding with factor H modulates the activation of the alternative pathway (72), while the recruitment of C4BP on ECM and apoptotic cells increase the rate of C4b-inactivation and reduce the deposition of the lytic C5b-9 terminal complex (73), limiting in both cases the complement activation (74). 
Other than complement, fibroblast growth factor 2 (FGF2), TNF--induced protein 6 (TSG6), myeloid differentiation protein 2 (MD-2) and inter--inhibitor (II) bind to the N-terminal domain of PTX3, while P-selectin interact with the pentraxin-like domain (64, 75–77). In addition, PTX3 recognizes Fc receptor (FcR), in particular FcRIII and FcRIIa (with a lower affinity). The opsonic activity of PTX3 appears to be dependent on FcRIIa and the complement receptor 3 (CR3; CD11b/CD18) (56, 70, 78, 79).

Recognition of apoptotic cells and debris by PTX3
Apoptosis (or programmed cell death) is a process of controlled cell death occurring during embryogenesis, development, homeostasis, tissue turnover and resolution of inflammation (80). Around one million cells undergo apoptosis in various tissue every second in adult humans (81). Apoptotic cells however are rarely seen in physiological conditions, indicating that the rate of apoptotic cell removal is high. Upon tissue injury and inflammation, a large number of apoptotic cells are generated. Rapid and efficient clearance of apoptotic cells by phagocytes is required to prevent loss of cell integrity, tissue damage and further activation of immune cells (31). Macrophages and dendritic cells internalize apoptotic cells and cross-present the processed antigen to T cells (82). In physiological conditions, the clearance of apoptotic cells by phagocytes mostly results in the induction of tolerance to self-antigens. However when the clearance is impaired, not only apoptotic cells undergo secondary necrosis, with the release of toxic and inflammatory intracellular components and subsequent tissue damage (see above), but the cross-presentation of autoantigens prompts the clonal expansion of autoreactive T cells, enforcing a vicious circle through which deregulated cell death and autoimmunity sustain and amplify each other (69). Indeed autoantibodies preferentially recognize autoantigens clustered within apoptotic blebs in the prototypic systemic autoimmune disease, SLE (83). In the context of SLE, glomerulonephritis (GLN) represents a major causes of morbidity and mortality (84) and immunization of autoimmune-prone mice, but not of normal mice, with syngeneic apoptotic thymocytes triggers both the establishment of autoantibodies and a disease that closely resembles human GLN  (85, 86). 
Anti-PTX3 antibodies have been described and characterized in human and experimental SLE (87). Patients with lupus GLN display lower levels of anti-PTX3 and higher levels of anti-C1q antibodies, suggesting that these antibodies influence the progression of the disease (88, 89). A recent study on a murine model of SLE demonstrated that immunization with PTX3 and the consequent development of anti-PTX3 antibodies result in delayed formation of nephrogenic antibodies, reduced proteinuria and better prognosis (90). It is tempting to speculate that protection from lupus GLN might depend on interference with the ability of PTX3 to activate and amplify the activation of the complement cascade.
	Both complement system and pentraxins participate to the removal of dying cells in the circulation or within injured tissues (31, 91). CRP activates the classical complement pathway through the interaction with C1q during the initial stages of the apoptotic process (92, 93). Moreover, SAP binds to the chromatin released by dying cells displacing H1-core histones, thus solubilizing and facilitating the safe clearance of chromatin fragments  (94, 95). SAP-deficient mice spontaneously produce autoantibodies against chromatin and DNA and GLN  (96), even if the important effect of the genetic background on the expression of autoimmunity in this model suggests caution interpreting these  results (95).
	PTX3 in vitro regulates the clearance of post-apoptotic debris by phagocytes, interacting with molecules of the humoral immunity (Fig. 1), in particular complement and ficolins (97–99). Ficolin-1 in particular interacts on apoptotic cells with the N-terminal domain of PTX3 yielding heterocomplexes, whose recognition promotes macrophage phagocytosis and downregulation of IL-8 production (88). These results highlight a code by which PTX3 in the presence of other humoral innate signals defines the homeostatic response appropriate to the clearance of dying cells or selects appropriate protective responses upon recognition of microbes (88).
	Fas-deficient mice spontaneously develop lympho-accumulation and features of lupus-like autoimmunity. The absence of PTX3 in this model results in a reduced clearance of apoptotic cells by peritoneal macrophages and a spontaneous lung inflammation. Conversely PTX3 accelerates the clearance of apoptotic T cell by peritoneal macrophages (100). In a model of acute sterile muscle injury, PTX3 has been shown to induce the removal of myofiber apoptotic remnants, contributing to the regeneration of the damaged myofibers and to the resolution of the inflammatory response (101). PTX3 and C1q stably bind to the membrane of apoptotic cells, interacting with different binding sites (102). Incubation of apoptotic cells with PTX3 results in an increased deposition of both C1q and C3 on cell surface. On the contrary, when the interaction between PTX3 and C1q occurs in fluid phase, an impairment of C1q and C3 deposition on apoptotic cells is observed, as well as a reduction of C1q-meditated phagocytosis by DCs and macrophages (Fig. 1) (97, 102, 103). 
	DCs in particular have a pivotal role in the removal of apoptotic cell debris and their presentation to T cells. PTX3 is stably bound to both the surface of dying cells and DCs: interestingly, the cross-presentation of epitopes deriving from PTX3-apoptotic cells to T cells is reduced, limiting tissue damage and activation of autoreactive T cell under inflammatory conditions (43, 104). In addition, PTX3-positive granules fuse to the cell surface of neutrophils undergoing late apoptosis, resulting in the translocation and accumulation of PTX3 in the apoptotic blebs of the plasma membrane. This event results in the expression of a further phagocytic tag, promoting rather than inhibiting the clearance of apoptotic neutrophils by phagocytes (98). 
	PTX3 acts also indirectly, as a negative modulator of the complement-mediated clearance of apoptotic cells. In fact, deposition of factor H (FH) on apoptotic cells reduces the complement-mediated lysis of these cells. PTX3 regulates the deposition of FH on the surface of dying cells, controlling the activation of the alternative pathway of the complement (72, 105). Specifically, surface-bound PTX3 increases the recruitment of FH and the deposition of iC3b, preventing the occurrence of an excessive inflammatory response to tissue injury (72). PTX3 directly interacts with FH and two different binding sites were identified at the C-terminal region of FH: the first in the short consensus repeat 7 (SCR7), interacting with the C-terminal domain of PTX3 (consistently with the demonstrated interaction of CRP with the same FH region) and the second in the SCR19-20, binding to the N-terminal domain of PTX3 (106). Mutations or polymorphisms of FH result in dysregulation of the alternative complement pathway and are associated with different diseases, such as the atypical haemolytic uremic syndrome (aHUS) and the age-related macular degeneration (AMD) (107, 108). In particular, it has been shown that a specific FH polymorphism in SCR7 (Tyr402His) significantly reduces the interaction between FH and CRP, decreasing the removal of drusen deposits and the clearance of cell debris, thus enhancing inflammation in AMD conditions (109). Of note, the same polymorphism does not influence PTX3-FH interaction, suggesting that PTX3 could be used to substitute the ineffective CRP in patients carrying the Tyr402His variant.
	PTX3 also recruits C4BP on ECM and apoptotic cells, increasing the rate of C4b-inactivation. Similarly, in presence of PTX3, the deposition of the lytic C5b-9 terminal complex is significantly reduced (73). Altogether, these results indicate the important role of PTX3 in the context of apoptotic cell clearance. On one hand, membrane associated, cell-bound PTX3 favours the rapid elimination of apoptotic cells to prevent the loss of their membrane permeability and the release of self-antigen and pro-inflammatory signals (52). On the other hand, soluble secreted PTX3 during inflammation counteracts the recognition of apoptotic cells in a pro-inflammatory setting, thus limiting immune responses against self-antigens (31).

PTX3 in the response to tissue damage and repair
 Pentraxins have been shown to play a central role in tissue remodelling both in physiological and pathological conditions (43). Several lines of evidence indicate a role of CRP in tissue damage, associated in particular to autoimmunity (110). In addition, in models of atherosclerosis, cardiac/ischemia reperfusion and cerebral infarct, CRP increases in injured tissue, inducing the complement cascade and contributing to tissue damage (111). In contrast, studies performed with transgenic human CRP in a ApoE-deficient mice did not show a pro-inflammatory and pro-atherogenic role for CRP (112). SAP exerts an anti-inflammatory effect in response to injury, regulating neutrophil recruitment and activation (113). It has been shown that SAP reduces inflammation and fibrosis in renal and lung disorders in vivo (114, 115). However, SAP binds to amyloid fibrils in systemic amyloidosis, Alzheimer’s disease and transmissible spongiform encephalopathy, contributing to the pathogenesis of the diseases by stabilizing amyloid deposits (116).
	The role of PTX3 in tissue remodelling and repair has been extensively demonstrated in physiological and pathological conditions (67, 101, 117–121). Originally, the role of PTX3 in tissue organization was identified analysing the infertility of female PTX3-deficient mice. The absence of PTX3 was associated to a defective assembly of the viscoelastic hyaluronan (HA)-rich matrix that forms around oocytes on preovulatory follicles (76, 117). During the preovulatory phase,  cumulus cell-derived PTX3 binds to TNF-induced protein 6 (TSG-6) and the serum proteoglycan Inter--trypsin inhibitor (II), contributing to the structural organization of the cumulus matrix.
	Via its N-terminal domain, PTX3 also binds to various fibroblast growth factors (FGFs), such as FGF2, FGF6, FGF8b, FGF10 and FGF17 (64, 122, 123), inhibiting endothelial cell-proliferation in vitro and angiogenesis in vivo (124). Interaction of PTX3 with FGF2 results in an inhibition of the FGF2-dependent activation of vessel-associated smooth muscle cells (SMC), FGF2-dependent angiogenesis and the consequent fibroblast migration and proliferation (122, 125). Moreover, PTX3 influences the late resolution phase in acute model of heart inflammation owing to ischemia/reperfusion: ballon injury of carotid arteries causes neointimal thickening as a consequence of maladaptive remodelling of the injured vessel wall, a process that is abrogated by the in situ PTX3 expression, artificially induced by gene transfer techniques (64, 125). 
	PTX3 is also associated with cardiovascular diseases and acute myocardial infarction (AMI) in particular. PTX3 deficient mice upon coronary artery ligation and reperfusion show a larger no-reflow area, increased tissue damage and neutrophil infiltration, decreased number of capillaries and higher number of apoptotic cardiomyocytes (126). In addition, a higher deposition of complement C3 was found in lesional tissues, possibly due to a defective regulation of complement activation via factor H (72, 126). Combined PTX3 and apolipoprotein E deficiency in a mouse model of atherosclerosis results in greater aortic lesions, characterized by a pronounced inflammatory profile in vascular walls and by macrophage accumulation within atherosclerotic plaques (127). PTX3 deficiency in a  mouse model of myocarditis induced by infection with coxsackievirus B3 results in an increased heart injury and cardiomyocyte apoptosis (128), either because of higher rates of cell death or poorly effective myofiber removal (see above). In a mouse model of arterial thrombosis, PTX3 localized into the thrombus and in the vessel wall dampens thrombogenesis by targeting fibrinogen and inhibiting platelet aggregation (129). The ability of PTX3 to regulate the reciprocal activation of neutrophils and platelets might contribute to its action on vascular homeostasis, limiting thrombotic events and maladaptive leukocyte activation within injured vessel walls (66). PTX3 is also an integral constituent of Neutrophil Extracellular Traps (65, 130, 131), microbicidal three-dimensional structures formed by decondensed chromatin decorated with neutrophil granular constituents (132, 133).  NETs have tissue-damaging and thrombogenic actions, at least partially mediated by histones. The ability of PTX3 to quench the potentially deleterious actions of histones (134–136) raises the interesting possibility that not all NETs are created equal, but that the rate of association with innate immune signals might modify their impact on the microenvironment. Further studies in vitro and in patients’ tissues (see below) are necessary to validate this hypothesis.
	PTX3 selectively binds to P-selectin, inhibiting leukocytes rolling on endothelium and reducing the recruitment of neutrophils into damage tissues, suggesting a negative feedback mechanism by which neutrophils control their own activation and persistent recruitment in inflamed tissues. This function has been clearly described in murine models of acute lung injury, pleurisy, mesenteric inflammation and post-ischemic acute kidney injury (137, 138). PTX3 also exerts a protective role in a mouse model of brain ischemic injury, being involved in edema resolution and glial scar formation, thus supporting the idea that PTX3 could be implicated in the integrity of the blood-brain barrier (139). 
	Recently, a non-redundant role of PTX3 through a novel mechanism has been demonstrated in murine models of tissue damage, including skin wound healing, chemically-induced sterile liver and lung injury and arterial thrombosis (67). After skin wound,  macrophages and mesenchymal cells express and release PTX3, that accumulates in the pericellular provisional fibrin matrix. PTX3-deficiency results in a defective pericellular fibrinolysis by macrophages and mesenchymal cells in vitro, together with an impaired directional migration in the provisional fibrin-rich inflammatory matrix in vivo. Increased fibrin accumulation and consequent collagen deposition/persistence in PTX3 deficient mice occurs in injured skin, liver and lung, in line with the role of fibrin as a provisional matrix protein driving the tissue repair processes (Fig. 1) (67, 140). 
	These events depend on the interaction of the N-terminal domain of PTX3 with fibrinogen and plasminogen at acidic pH. The acidification of the injured tissues is necessary for the interaction and guarantees that it occurs only within the damaged tissue and not in the circulation (44). Fibrinogenesis also play a crucial role in non-alcoholic fatty liver disease (NAFLD). Even if the majority of patients have a simple hepatic steatosis without signs of severe inflammation, in some cases progressive non-alcoholic steatohepatitis (NASH) fibrosis and cirrhosis develop. PTX3 (and CRP) levels are significantly higher in patients with NASH compared to non-NASH and associated with the degree of fibrosis (141, 142). It has therefore been suggested that PTX3 could be used as a biomarker to discriminate NASH and NAFLD patients, even if further investigation is needed for this purpose (143, 144).
Tumors are considered a “wound that does not heal” (145) and it is now generally accepted that inflammation plays a central role in the neoplastic progression (146–149). Different studies report increased local or systemic levels of PTX3 in several cancers, including soft tissue sarcoma (150), lung cancer (151), myeloproliferative tumors (152), pancreatic carcinoma (153), gliomas (154) and hepatocellular carcinomas (155), correlating in some cases with the progression of the disease. Gene expression and epigenetic regulation of PTX3 has also been associated with different human cancers. PTX3 gene is one of the most expressed gene related to the stromal response/ECM signature and poor prognosis in human ovarian cancer (156) and PTX3 genetic variant have been associated with increased plasma levels of PTX3 and risk of developing hepatocellular carcinoma in patients infected with hepatitis C-virus (155). PTX3 promoter and regulatory regions of the locus are highly methylated in human mesenchymal and epithelial tumors, in contrast to healthy tissues, suggesting that PTX3 methylation is responsible for the silencing of PTX3 protein expression (157, 158). PTX3 acts not only as an essential component of humoral immunity and a regulator of the complement activation and of tissue remodelling, but also as an extrinsic oncosuppressor gene in tumor development (159). In particular, PTX3 deficiency is associated with an increased susceptibility to mesenchymal and epithelial carcinogenesis in mouse model of 3-Methylcholanthrene–induced carcinogenesis and 7,12-dimethylbenz [] anthracene/terephtalic-induced skin carcinogenesis (158). In these models, PTX3 deficiency results in an exacerbated inflammation, characterized by an enhanced number of infiltrating tumor-associated macrophages, higher angiogenesis, higher production of pro-inflammatory cytokines and increased C3 deposition. In this system, increased inflammation is potentially related to genetic instability, as indicated by augmented mutation in Trp53 gene, oxidative DNA damage and expression of DNA damage markers (Fig. 1). 
	C3-genetic inactivation and CCL2-inhibition revert the enhanced susceptibility to mesenchymal carcinogenesis in PTX3-deficient mice, together with a reduction of the recruitment of tumor-associated macrophages and their M2-like phenotype, highlighting the upstream role of PTX3 in restricting carcinogensis in this model, most likely via its action in quenching complement activation and macrophage recruitment within the tumor (158). As previously discussed, PTX3 also interacts with several fibroblast growth factors (FGFs) and inhibits FGF-dependent angiogenic responses (64), including cancer-associated neoangiogenesis (123). In  mouse TRAMP-C2 prostate cancer and B16 melanoma models, PTX3 overexpression results in a reduced FGF-dependent tumor growth, melanoma metastasis and cancer-associated angiogenesis (160). However in head and neck tumors, PTX3 appears to promote tumor cell migration and invasion, while in gliomas tumor cell proliferation (161, 162). In gastric cancer, PTX3 expression is associated with the extent of tumor cell invasion, and PTX3 gene silencing results in a reduced cancer-related inflammation (163).
	All together these results point to a flexible role of PTX3 in damaged tissue, that comprises interaction with various ligands, regulation of the activation of the complement system, of angiogenesis and of the organization of the ECM. Protective and deleterious roles have been described, mostly depending on the tissue district and the general condition of inflammation.

Regulation of leukocyte recruitment in concert with chemokines.
As discussed above, several evidences point out to a direct role of PTX3 on neutrophil recruitment to the site of inflammation (137). In particular, PTX3 released by hematopoietic stem cells restricts the P-selectin-dependent recruitment of neutrophils, thus acting as a negative feedback regulator upon acute lung injury (137) and kidney ischemia and reperfusion (138). Conversely Ptx3 deletion induces an exacerbated allergen-induced inflammation in a model of ovoalbumin-induced experimental asthma (164). The absence of PTX3 results in an enhanced recruitment of neutrophils and eosinophils, increased mucus production and secretion of IgE/IgG2a. Ptx3-deficient mice showed a Th17-dominant CD4+ T cell response, likely due to the higher production of IL-6 and IL-23 by DC, thus inducing a Th17/T cell polarization. PTX3 deficiency increases mouse susceptibility to invasive pulmonary aspergillosis, with an augmented Th2 response and a reduced protective Th1 antifungal response. Interestingly, treatment with exogenous recombinant PTX3 revert the phenotype inducing a protective Th1 response, possibly by facilitating conidia phagocytosis by antigen-presenting cells (56, 165). Increased tumor-associated macrophage infiltration occurs in the absence of PTX3, consistent with the increased production of the chemokine CCL2 (158). 
Chemokines have been shown to be involved in a number of acute and chronic inflammatory conditions by promoting the infiltration and activation of inflammatory cells into damage tissues and contributing to angiogenesis and tissue repair (166–168). CC chemokines like CCL3 and CCL5 are expressed in sepsis and mediate leukocyte recruitment and activation in infected organs (169, 170). CXC chemokine-mediated stimulation of neutrophils is fundamental for the clearance of invading bacteria in pneumonia (171). Chemokine expression correlates with influx in airways of specific leukocyte subsets: in chronic obstructive pulmonary disease (COPD) CXCL9, CXCL10, CXCL11 and CCL5 are responsible for the recruitment of T cells and eosinophils (172). Atherosclerosis is widely considered a chronic inflammatory disease, characterized by the presence of different leukocytes (such as T and B cells, NK cells, macrophages, DC and mast cells) within atherosclerosis-prone aortas. In this context, monocyte recruitment involves P-selectin, CCL2, CX3CL1 and CCL5, while T and B lymphocytes migrate into the atherosclerotic wall in a L-selecting manner and in response to several chemokines, such as CCL5, CXCL10 and CXCL16 (173). 
	Chemokines have a pivotal role in carcinogenesis, regulating different aspects of tumor progression such as leukocyte recruitment, angiogenesis and metastasis (174–178). CC chemokines, such as CCL2 and CCL5, are major attractant of macrophages to the tumor microenvironment and tumor-associated macrophages have been widely associated with an M2-like phenotype with tumor-promoting properties (4, 179). Similarly, CC and CXC chemokines control lymphocyte trafficking in cancer, which have a predominant Th2-, tumor promoting phenotype (177, 180). In addition, the chemokine CXCL12 and its receptor CXCR4 are overexpressed in various cancers.  In healthy conditions the CXCL12-CXCR4 axis is important for hematopoietic stem cell homing and vascular development. In contrast the aberrant expression of these signals in tumors promotes neoplastic cell proliferation, migration and invasion through multiple signalling pathways (181). Evidence of a non-redundant role of inflammatory CC chemokine in carcinogenesis have been provided by analysing the involvement of atypical chemokine receptor, such as D6. D6 acts as decoy receptor, preventing worsened chemokine signalling during inflammatory response and mice lacking D6 expression have an increased inflammation-related cancer (182, 183).

Clinical translation as a biomarker of tissue and vascular damage
PTX3 is a well-described acute phase protein, whose plasmatic levels increase rapidly from a basal level of approximately 2ng/ml in healthy conditions to hundreds ng/ml during endotoxic shock, sepsis and other infectious or inflammatory conditions (62). Data from AMI and meningococcal sepsis show that PTX3 peaks 6-8h after injury, while CRP increases after 24-30h. The different kinetics can be explained by the nature of PTX3 and CRP induction. As previously discussed, CRP is systemically produced by the liver in response to IL6 while PTX3 is secreted in inflamed tissues in response to primary inflammatory cytokines or microbial recognition (184). 
	In the context of infection, PTX3 levels are widely associated with the severity of the disease. In a cohort of 101 consecutive patients with systemic inflammatory response syndrome (SIRS), sepsis or septic shock, PTX3 plasma concentrations were increased, with a gradient consistent with the severity of the disease (from SIRS to septic shock) and acting as a predictive factor of mortality (185). Similarly, in a Danish study on 261 patients admitted to intensive care unit for SIRS, higher expression of PTX3 correlates with sepsis and septic shock (186). In the absence of infection, a “sepsis-like” syndrome is observed after cardiopulmonary resuscitation. In conditions of total body ischemia and reperfusion, the systemic inflammatory response is characterized by the presence of endotoxin in plasma, deregulation of cytokine production and coagulation defects. In these situations, PTX3 expression in plasma increases and is associated with an enhanced risk of multiple organ dysfunction syndrome (187).
PTX3 expression has been associated with sterile inflammation and has been studied extensively in patients with cardiac and vascular diseases. In patients with AMI, PTX3 levels rapidly increase, correlating with the severity of the disease (188). Of note, PTX3 has been demonstrated to be the only independent predictor of mortality within 3 months from the event (189). In addition, PTX3 levels reveal atherosclerosis (190, 191) and have been associated with disease severity and mortality in heart failure (192), stroke (193) and upon resuscitation from cardiac arrest (187).  
PTX3 blood levels are increased in most human diseases in which the involvement of the vasculature is critical. This includes the common vascular complication of pregnancy, pre-eclampsia (194–197) and systemic vasculitis. Systemic vasculitis are heterogeneous diseases, characterized by primary self-sustaining inflammatory damage of the wall of various groups of vessels and by the ensuing multiorgan systemic involvement.
Small vessel Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis comprises relapsing-remitting disease characterized by i) autoimmunity to antigens expressed by polymorphonuclear leukocytes and by ii) their paroxysmal activation and intempestive degranulation upon extravasation (198, 199). PTX3 is one of the limited array of neutrophil antigens specifically recognized  by ANCA (200) and its levels: i) are elevated independently of those of other pentraxins; ii) reflect synthesis at inflamed sites; iii) have been associated with leukocytoclasia, i.e. accumulation of neutrophil debris in peripheral tissues and iv) are modulated by the activity of the disease and by immunosuppressive treatments (103, 201–203). Studies are ongoing to verify whether PTX3, besides an interesting biomarker, might be involved in ANCA-associated vasculitis in the negative regulation of neutrophil activation and survival (133).
Granulomatous segmental involvement of the aorta and its branches identify large vessel vasculitis, in which leukocytes infiltrate the vessel wall and guide a maladaptive response to injury occurs. The response comprises fragmentation of elastic membranes, damage of the medial layer, neoangiogenesis, activation and accumulation of myofibroblasts and eventual intimal hyperplasia (204–206), probably because of a failure of locally generated signals that curb immune activation and the associated vessel damage and remodeling (206). PTX3 is generated within the inflamed vessel wall by endothelial cells of the vasa vasorum or by infiltrating macrophages and is found associated to the remodeling matrix (207).  PTX3 induction has been initially associated to the inflammatory state of these patients. However it appears increasingly clear that elevated levels identify subgroups of patients, such as those undergoing ischemic complications that represent the evolution of vacular lumen occlusion, such as optic neuritis in Giant Cell Arteritis (207) or progression of the vascular involvement because of unrestrained mural remodeling in Takayasu Arteritis (208). The availability of novel, more refined non-invasive imaging approaches will be instrumental for a better stratification of patients with large vessel vasculitis in homogenous groups (209, 210).
Of interest, patients with large vessel vasculitis are often treated with anti-cytokine agents targeting in particular TNF-α and IL-6. PTX3 identified vascular progression only in patients who were not being treated with anti-TNF-α agents (208), in good agreement with the role of the cytokine as a major stimulus driving PTX3 expression in vivo (see above).
Acute Graft-versus-Host Disease (GvHD) accounts for the 15-30% of allogeneic stem cell transplant (HSCT)-related mortality (211). PTX3 has been investigated as a biomarker of acute GvHD, by monitoring plasma levels in a cohort of 115 pediatric patients undergoing HSCT for hemato-oncological disease (212). PTX3 plasma levels increase in patients experiencing clinical symptoms of the disease and have predictive values, being significantly higher in severe and therapy-unresponsive patients.  These results suggest that PTX3 could be used as a marker for GvHD severity and therapy response, useful for tailoring treatment intensity and anti-GvHD therapy.
Recently, PTX3 was also found to have a role also in polycythemia vera (PV) and essential thrombocythemia (ET), two myeloproliferative neoplasms (MPNs) characterized by clonal expansion of abnormal haematopoietic progenitor cells, frequent cardiovascular complications and increased risk of transformation to myelofibrosis or acute leukaemia (213). The driver mutations JAK2V617F, MPLW515L/K and CALR strongly influence disease phenotype of MPNs, possibly sustaining a condition of chronic inflammation. PTX3 levels indeed were higher in patients carrying homozygous JAK2V617F mutation. Interestingly, the risk of haematological progression and of death was increased in patients with high levels of PTX3, while the thrombosis rate tended to be reduced. These results indicate that JAK2V617F mutation influences MPN-associated inflammation and that PTX3 might have a prognostic value for patients with ET and PV, even if further investigations are needed (152, 214).
In the last years, several studies analysed single-nucleotide polymorphism (SNPs) in PTX3 gene, finding 3 SNPs associated with susceptibility to infections. A particular PTX3 haplotype has been associated with the risk of tubercolosis in West Africa (215). In patients with cystic fibrosis PTX3 haplotype frequencies are different between patients with P. aeruginosa colonization compared to non-colonized subjects (216). In addition, PTX3 variants are associated with increased susceptibility to fungal infection in solid organ transplanted patients (217), to urinary tract infection (218) and to invasive aspergillosis in patients undergoing hematopoietic stem-cell transplantation (219). 
Taking together, these results indicate the potential use of PTX3 as an important biomarker in different context of human pathologies, including infection-caused and sterile tissue damage.

Concluding remarks
	In concert with cells of the immune system, in particular phagocytes, and with other components of the humoral innate response, such as the complement system and ficolins, PTX3 is necessary for the recognition and rapid clearance of apoptotic cells, preventing membrane disruption and the release of self-antigen and of endogenous inflammatory signals. PTX3 acts as a regulator/indicator of inflammation and modulator of complement activation, exerting a pivotal role in the pathogenesis and possibly treatment of several diseases, including AMD, AMI, GvHD, MPNs, pregnancy complications, vasculitis and sepsis. Interacting with plasminogen and fibrin in acidified wound site, PTX3 promotes fibrinolysis, playing a crucial, non-redundant role in the process of tissue repair. In addition, in concert with chemokines, PTX3 orchestrates recruitment of leukocytes at the site of damage, contributing to shaping the inflammatory microenvironment and terminating the response. The regulation of the complement activation and of the composition of the inflammatory microenvironment are also essential in the recently described oncosoppressive role of PTX3. The finding that a component of the humoral immunity is a bona fide “cancer gene” enforces the well-established connection between cancer and inflammation. Results obtained from the carcinogenesis model in PTX3-deficient mice, further sustained by data in human cancers, point to the potential different functions of this protein in a variety of tumors, supporting the need of fully dissecting its role in carcinogenesis. Finally, clinical evidence of different PTX3 levels in several pathological contexts underline the potential role of this protein as a candidate for prognostic and predictive analysis in a variety of human diseases. 
	Taken together, the results summarized in this review indicate that PTX3 action integrates innate immunity, inflammation, ECM organization, tissue remodelling/repair and cancer, providing a rationale for its use as a diagnostic biomarker and a therapeutic tool. 
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